USA: Kraig Biocraft Laboratories Launches Commercial Production of Monster Silk(TM)

USA: Kraig Biocraft Laboratories Launches Commercial Production of Monster Silk(TM)

Kraig Biocraft Laboratories, Inc., the leading developer of advanced spider silk based fibers, announced the launching of the company’s commercial production program with the recent hatching of its first batch of Monster Silk(TM) silkworms for commercial production. Furthermore, the company is currently expending resources to augment the scale of its Monster Silkworm(TM) production over the next 30 to 90 days, in keeping with its planned strategy. The company’s strategy is to commit the vast majority of its initial production capacity to a propagation program designed to increase its production population. A smaller portion of the first commercial production generation should also yield fibers which can be dedicated to the production of woven textile samples.

“Our launch of our commercial scale production of Monster Silk(TM) is a long awaited major milestone for Kraig, as we demonstrate our ability to convert recombinant spider silk, and Monster Silk(TM) most specifically, from an exciting laboratory technology to a marketable product,” said, CEO and founder, Kim K. Thompson. “It has taken many years to go from my initial concept of recombinant spider silk to the laboratory production of Monster Silk(TM) and now the actual launch and scaling up of the commercial scale production. I want to thank our investors and, most particularly, the research scientists, whose work and dedication has made this long anticipated day possible.”

“Given the current planned production schedule, we could theoretically be producing Monster Silk(TM) in metric ton quantities by early January. A more conservative estimate, given the realities of launching such a ground breaking and commercially unique project, would be to reach that major milestone in mid 2014. This move reaffirms our view that Kraig is the world’s leading developer of recombinant spider silk technologies,” concluded Thompson.